NCT00869726

A Study for Patients With Secondary Progressive Multiple Sclerosis

A Double-Blind, Placebo Controlled Multicentre Study To Evaluate The Efficacy And Safety Of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 596 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether MBP8298 is effective and safe in the treatment secondary progressive multiple sclerosis. Dirucotide is generic name for MBP8298.

Conditions

• Secondary Progressive Multiple Sclerosis

Interventions

Type	Name	Description
DRUG	dirucotide	500mg, intravenous, dosed once every six months for 18 months
DRUG	Placebo	intravenous, once every six months for 18 months

Timeline

• Start date: 2004-12-01
• Primary completion: 2009-05-01
• Completion: 2009-05-01
• First posted: 2009-03-26
• Last updated: 2010-06-02

Locations

10 sites across 10 countries: Canada, Denmark, Estonia, Finland, Germany, Latvia, Netherlands, Spain, Sweden, United Kingdom